Drug Profile
Research programme: CD26 antigen antagonists - Phenomix
Alternative Names: Dipeptidyl peptidase IV anatagonists - Phenomix Corporation; DPP-IV antagonists - Phenomix Corporation; PHX 1004Latest Information Update: 04 Feb 2011
Price :
$50
*
At a glance
- Originator Phenomix Corporation
- Class Antihyperglycaemics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus